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association between medication adherence and quality of life (QoL) in Iranian women with epilepsy (WWE).
Methods:Women's sexual functioning was measured using Female Sexual Function Index; QoL using Quality of
Life in Epilepsy; epilepsy severity using Liverpool Seizure Severity Scale; subjective medication adherence using
Medication Adherence Report Scale; and objective medication adherence using serum level for antiepileptic
drugs in 567 WWE. Medication adherence was measured at baseline, while women's sexual functioning, QoL,
and epilepsy severity were measured at the 6-month follow-up. Structural equation modeling and regression
models were conducted to examine the mediating role of women's sexual functioning.
Results: Themediating effects of sexual functioning in the relationship betweenmedication adherence (including
subjective and objective measures) and QoL were supported in the total score of Female Sexual Function Index
(coefﬁcient = 0.415, SE = 0.117, p b 0.001 for subjective medication adherence; coefﬁcient = 1.980,
SE = 0.446, p b 0.001 for objective medication adherence). Seizure severity was signiﬁcantly associated with
QoL but onlywhenobjectivemedication adherencewasmeasured (coefﬁcient=−0.094, SE=0.036, p=0.009).
Conclusion: Our results extended the importance of medication adherence from symptom reduction to the bene-
ﬁcial effects of women's sexual functioning and QoL. Health care providers should be aware of these additional
beneﬁts of medication adherence and use these arguments to encourage female patients to take their medication,
which can eventually increase their sexual satisfaction and overall QoL.
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Sexuality is an important component of quality of life (QoL) in
women and men. This is, for example, reﬂected in the World Health
Organization Quality of Life Questionnaire, where the item “Are you
satisﬁed with your sexual life?” is included in the list of questions [1].
Thus, sexuality has to be considered an integral part in an individual's
life [2]. Many chronic disorders and conditions have been shown to
have detrimental effects on a person's well-being by negatively
impacting sexual QoL (sQoL) [3,4]. This is also true for people with epi-
lepsy (PWE). According to a review conducted in 2005, about 20% to
30% of women with epilepsy (WWE) report some form of sexualtic drugs; FSFI, Female Sexual
psy:; LSSS, Liverpool Seizure
le; DWLS, Diagonally weighted
with epilepsy.
ealth Research Center (SDH),
vd, Qazvin 3419759811, Iran.
r@qums.ac.ir (A.H. Pakpour).dysfunction, including decreased libido or problems with arousal and
infrequent orgasms [5]. Women with epilepsy have further been
shown to have an earlier onset of menopause [6] which consequently
may affect their sexual life due to the inﬂuence of menopause-
associated changes in sex hormones [7]. Other factors observed to
inﬂuence sexual functioning in WWE include anxiety, stigmatization,
epileptic activity in cortex, and certain antiepileptic drugs (AEDs) [5,8].
AlthoughAEDsmay increase awoman's risk for sexual problems due
to a range of previously reported drug-related side-effects such as
changes in sex hormones [5,9], it is equally possible that the treatment
beneﬁts of AEDsmay outweigh these negative consequences for a num-
ber of reasons. First, AEDs can improve disease symptomswhich in turn
can lead to a reduction of anxiety and can soften the stigma sufferers
often report to be associated with the condition [10]. By decreasing
anxiety and minimizing the stigma, women's sexuality may indirectly
beneﬁt, especially given the fact that anxiety has repeatedly been
reported to be an important risk factor in the development of sexual
problems [11]. Second, although some AEDs have been shown to
lower certain reproductive hormones [10], this is not the case for all
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seizure-free women with epilepsy and taking a range of AEDs, and
found that valproate in contrast to carbamazepine, did not signiﬁcantly
change free testosterone levels. Similarly, a study conducted by Stephen
and colleagues [12] where PWE were randomly assigned to either a
group taking valproate or lamotrigine, showed no changes in total tes-
tosterone after 6 and 12months of treatment in either group. Yet anoth-
er study of 141 PWE (of which 66 were women) demonstrated that
lamotrigine even improved sexual function in WWE after changing
their AEDs [13]. Overall, it seems that some AEDs can improve epilepsy
symptoms without necessarily exerting a negative impact on sexual
functioning.
Research has also shown medication adherence to be closely
linked to QoL in PWE [14]. People with epilepsy have a high rate of co-
morbidities (e.g., attention-deﬁcit hyperactivity disorder symptoms
and mood disorders) and other somatic and psychological symptoms
which substantially and negatively inﬂuence their QoL [15,16]. Fortu-
nately, most of the seizure symptoms and negative consequences of
the comorbid conditions can be overcome by means of the prescribed
AEDs [17]. In this regard, several studies have provided evidence for a
positive association between higher level of medication adherence
and better QoL in PWE [18–20]. It is, therefore, legitimate to conclude
that medication adherence plays an important role for QoL in WWE.
Despite strong evidence for a link between sexuality and QoL [21],
between medication adherence and sexuality [13], and between medi-
cation adherence and QoL [14,18–20], no studies simultaneously
examine the three factors (sexuality, QoL, and medication adherence).
Further exploration and identiﬁcation of mediators of QoL can provide
health care providers with additional insights on how to improve
female QoL and offer strong reasons to counsel WWE to adhere to
prescribed medication to increase their QoL.
Therefore, the aim of the studywas to examine themediating effects
of female sexual functioning in the relationship betweenmedication ad-
herence and QoL in an Iranian sample of WWE. Sexual functioning was
measured across 6 individual domains and assessment of medication
adherence included both a subjective and objective measure.
2. Methods
2.1. Sample, recruitment, and study procedure
This longitudinal studywas carried out across four neurologic clinics
in Qazvin and Tehran between October 2015 and June 2016; and
targeted a sample of WWE. The study was approved by the Ethics
Committee of Qazvin University of Medical Sciences prior to participant
recruitment and all participants provided informed consent before en-
tering the study. Inclusion criteriawere: being an 18+-year-old female,
being in a stable sexual relationship with a male partner for at least the
past 6 months, and having been diagnosed with epilepsy according to
the International League Against Epilepsy criteria [22]. Patients with
other chronic diseases including diabetes mellitus, cardiovascular
diseases, hypertension, rheumatic diseases, kidney disease, severe
mental and psychiatric disorders, substance abuse or pregnancy, were
excluded from the study because of the likely interference with their
sexual functioning.
Every patient interested in participating and providing informed
consent was screened for eligibility by two trained physicians. After-
ward, two trained research assistants informed the potential partici-
pants about the study aims, and those willing to participate were
asked to sign an informed consent. The study measures were provided
for the patients with assistance in a quiet and private clinic room after
the patient visited the physician. A small portion of the patients (13%)
did not receive formal education, which means that we recruited both
literate and illiterate participants. For the illiterate patients, a trained re-
search assistant read all questions including the response scale for them
without any further guidance. Identiﬁed eligible patients completed abaseline assessment consisting of a questionnaire asking about socio-
demographic information (including age, educational attainment, and
monthly income) and self-reported medication adherence. Moreover,
blood samples were collected on the same day as an objective measure
of AED adherence. Six months later, the patients were re-contacted by
telephone and asked to attend the clinic to complete a set of question-
naires assessing sexual functioning, QoL, and seizure severity. Of the
703 patients identiﬁed as meeting the eligibility criteria, 19% (n =
136) did not agree to participate in the study, resulting in a ﬁnal sam-
ple of n = 567. The dropout rate after 6 months was 3.3% (n = 18).
2.2. Instruments
2.2.1. Female Sexual Function Index
The Female Sexual Function Index (FSFI) is regarded as the gold-
standard for the assessment of women's sexual functioning [23]. It
includes 19 items which tap into the following six domains: sexual de-
sire (2 items), arousal (4 items), lubrication (4 items), orgasm (3 items),
satisfaction (3 items), and pain (3 items). Except for four items (2 in
the desire and satisfaction domains each) with scores that range be-
tween 1 and 5, all other items have a score ranging from 0 and 5,
with a higher item score indicating better sexual functioning.
Subdomain scores can be computed by adding up the relevant items
and multiplying it by a predeﬁned subscale weight. The known-
group validity of the FSFI has been supported based on its capability
to detect signiﬁcant differences between women with sexual arousal
disorder and women without such problems. A translated and
validated Persian version of the FSFI exists which – similar to the origi-
nal English version – has shown satisfactory internal consistencies
(α=0.72 to 0.90) and high test–retest reliability (intraclass correlation
coefﬁcient = 0.73 to 0.86) [24].
2.2.2. Quality of life in epilepsy
The Quality of Life in Epilepsy (QOLIE-31) instrument includes 31
items, of which one item is a visual analogue scale and the other 30
items are ordinal scales. Questions are responded to on a 6-point
Likert-type scale. The QOLIE-31 captures seven domains: seizure
worry (5 items), cognitive function (6 items), energy/fatigue (4
items), emotional well-being (5 items), social function (5 items), med-
ication effects (3 items), and overall QoL (2 items). Based on the
developer's instruction, each domain score can be converted into a 0–
100 scale, with a higher score representing better level of QoL [25]. In
addition, an overall questionnaire score can be computed by summing
up the average scores of the seven domains. Like the original English
version, the psychometric properties of the translated Persian version
were satisfactory with high test–retest reliability (r = 0.68) and good
internal consistency (α= 0.90) [25,26].
2.2.3. Liverpool Seizure Severity Scale
The Liverpool Seizure Severity Scale (LSSS) includes 20 items rated
on a 4-point Likert-type scale with higher scores indicatingmore severe
seizures. The known-group validity of the LSSS can be rated
as satisfactory as it differentiates well between people with severe
seizure symptoms and those with minor seizure symptoms [27]. The
LSSS has been translated into Persian with excellent internal consisten-
cy (α=0.90), test–retest reliability (intraclass correlation coefﬁcient=
0.96), and criterion-related validity (r=−0.43with the total QOLIE-31
score) [28].
2.2.4. Medication Adherence Report Scale
The Medication Adherence Report Scale (MARS) is used for the as-
sessment of subjective medication adherence and includes ﬁve items
rated on a 5-point Likert-type scale, scoring from never (1) to always
(5). Adding up all items yields a total score with a score equal or greater
than 20 suggesting high level ofmedication adherence [29]. The concur-
rent validity of the MARS has been supported bymeans of correlational
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Fig. 1. Conceptual models: (a) Model 1; (b) Model 2; (c) Model 3; (d) Model 4. aMedication adherence could be either MARS or serum level. bFSFI could be each domain score or the total
score.
Table 1
Descriptive analyses of instruments scores (n = 567).
Instrument Mean SD Range (min, max)
Domain
QOLIE-31 67.01 20.70 (10.7, 99.1)
Seizure worry 75.49 35.83 (0.0, 100.0)
Cognitive function 64.79 43.10 (0.0, 100.0)
Energy/fatigue 59.05 18.51 (0.0, 100.0)
Emotional well being 61.11 19.07 (4.0, 100.0)
Social function 77.76 21.99 (0.0, 100.0)
Medication effects 78.43 24.89 (0.0, 100.0)
Overall quality of life 61.06 20.41 (0.0, 100.0)
FSFI 17.61 10.10 (1.2, 36.0)
Desire 3.43 1.61 (1.2, 6.0)
Arousal 2.77 2.08 (0.0, 6.0)
Lubrication 2.67 2.43 (0.0, 6.0)
Orgasm 2.66 2.34 (0.0, 6.0)
Satisfaction 3.30 2.02 (0.0, 6.0)
Pain 2.80 2.39 (0.0, 6.0)
LSSS 54.05 23.89 (4.6, 89.4)
MARS 13.23 6.66 (5.0, 25.0)
QOLIE-31: Quality of Life in Epilepsy; FSFI: Female Sexual Function Index; LSSS: Liverpool
Seizure Severity Scale; MARS: Medication Adherence Report Scale.
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tion serum concentrations (r = 0.52) [30].
2.2.5. Serum levels for antiepileptic drugs
Serum antiepileptic drug levels were measured in the blood
samples taken prior to the administration of the next routine drug
dose, using a microparticle enzyme immunoassay (Abbott Axsym®,
Abbott Laboratories, Abbott Park, IL, USA). Based on the suggested levels
for therapeutic range [31], we classiﬁed all the data into either non-
adherence (i.e., below the therapeutic range) or adherence (i.e., within
or above the therapeutic range).
2.3. Data analysis
Data were analyzed using SPSS 23.0 (for descriptive statistics) or
R software with lavaan package (for the effects of medication
adherence and FSFI scores on QoL). Demographics and main variable
characteristics were reported using descriptive statistics, including
frequencies and percentages for categorical data and mean and SD for
continuous data. The associations between medication adherence and
QoL (Model 1, see Fig. 1a), between medication adherence and sexual
functioning (Model 2, see Fig. 1b), and between sexual functioning
and QoL (Model 3, see Fig. 1c) were determined using linear regression
models that controlled for age, education, income, and the LSSS score.
The mediating effects of sexual functioning in the relationship between
medication adherence and QoL were tested using structural equation
modeling that controlled for the same confounders as did Models 1 to
3 (Model 4, see Fig. 1d). A bootstrap method with 1000 resampling
was used to decide on the signiﬁcance of the mediating effects. Two
sets of Models 1 to 3 were performed depending on the two different
measures of medication adherence (i.e., MARS vs. serum levels). The
signiﬁcance level was set at p b 0.05 using a two-sided test. All regres-
sion and structural equation modeling analyses were estimated using
diagonally weighted least squares (DWLS), specially designed for ordi-
nal variables such as the present Likert-type scales [32].
3. Results
The mean± SD age of the 567 participants was 35.8 ± 13.03 (range
18 to 73 years). Average years of education was 8.8 ± 5.16 (range 0 to
18 years; the mean year), and mean years since diagnosis was 6.36 ±
4.65 (range 1 to 28 years). About 50% of the participants were house-
wives (n = 249, 43.9%), less than 10% were students (n = 53, 9.3%),
and about 5% were retired (n = 29, 5.1%). The most prevalent type ofepilepsy was idiopathic generalized epilepsy (n = 265, 46.7%), followed
by cryptogenic partial epilepsy (n = 164, 28.9%) and symptomatic
partial epilepsy (n = 138, 24.3%). In almost half of the participants, the
antiepileptic drug serum level was below the usual therapeutic range
(n= 283, 49.9%). Nearly two-thirds of the patients received polytherapy
(n = 364, 64.2%), and slightly more than one-third received monothera-
py (n = 203, 35.8%). No signiﬁcant differences were found between
patients who received polytherapy and those who received monother-
apy in QOLIE-31 (p = 0.14 to 0.99), FSFI (p = 0.30 to 0.98), MARS
(p = 0.11), age (p = 0.29), and education level (p = 0.11).
Themean± SD score of the QOLIE-31 total scorewas 67.01± 20.70,
and the mean domain scores of the QOLIE-31 were between 59.05
(energy/fatigue) and 78.43 (medication effects). The mean FSFI total
score was 17.61 ± 10.10, and the mean domain scores of the FSFI
were between 2.66 and 3.43. The mean LSSS score was 54.05 ± 23.89,
and the mean MARS score was 13.23 ± 6.66 (Table 1).
The mediating effects of sexual functioning in the relationship be-
tween medication adherence and QoL were supported for the FSFI
total score and for the subdomains of lubrication, satisfaction, and
painwhen usingMARS score as a subjectivemeasure formedication ad-
herence. Furthermore, sexual functioning, including all the subdomains
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when the variables age, education, income, and seizure severity were
controlled, the following correlations were found: self-rated medica-
tion adherence and QoL (coefﬁcient = 0.646, SE = 0.142, p b 0.001)
in Model 1; medication adherence and overall sexual functioning
(coefﬁcient = 0.952, SE = 0.055, p b 0.001) in Model 2; overall sexual
functioning and QoL (coefﬁcient = 0.509, SE = 0.088, p b 0.001)
in Model 3. Medication adherence and QoL were not correlated
(coefﬁcient = 0.250, SE = 0.197, p = 0.20) when overall sexual
functioning was simultaneously included in Model 4, but overall sexual
functioning was correlated with self-rated medication adherence
(coefﬁcient = 1.000, SE = 0.047, p b 0.001) and QoL (coefﬁcient =
0.415, SE = 0.115, p b 0.001). Also, mediating effects of the overall
sexual functioning were found (coefﬁcient = 0.415, SE = 0.117,
p b 0.001) in Model 4.
When relying on objective blood serum levels, the mediating effects
of sexual functioning could be observed for all subdomains and the total
FSFI score, except for desire. Speciﬁcally, controlling age, education,
income, and seizure severity, the objective medication adherence andTable 2
Mediating effects of sexual functioning in the relationship between subjectively assessed medi
Dependent variablea Independent variable: coefﬁcient (SE)
Age Education Income LSSS
M1:QoL −0.123 (0.072) 0.262 (0.180) −3.421 (1.159)⁎⁎ −0.02
FSFI using Total score
M2:FSFI 0.008 (0.028) 0.061 (0.069) −0.109 (0.445) −0.03
M3:QoL −0.131 (0.071) 0.233 (0.179) −3.493 (1.151)⁎⁎ −0.03
M4:FSFI – – – –
M4:QoL −0.122 (0.076) 0.252 (0.177) −3.450 (1.330)⁎⁎ −0.01
FSFI using Desire domain score
M2:FSFI 0.000 (0.005) 0.009 (0.013) 0.055 (0.086) −0.00
M3:QoL −0.149 (0.072)⁎ 0.216 (0.183) −3.730 (1.176)⁎⁎ −0.08
M4:FSFI – – – –
M4:QoL −0.122 (0.079) 0.262 (0.175) −3.537 (1.321)⁎⁎ −0.02
FSFI using Arousal domain score
M2:FSFI −0.006 (0.005) 0.017 (0.014) −0.015 (0.088) −0.00
M3:QoL −0.125 (0.072) 0.224 (0.182) −3.577 (1.170)⁎⁎ −0.06
M4:FSFI – – – –
M4:QoL −0.115 (0.078) 0.268 (0.179) −3.489 (1.272)⁎⁎ −0.02
FSFI using Lubrication domain score
M2:FSFI 0.009 (0.008) 0.023 (0.020) −0.013 (0.125) −0.00
M3:QoL −0.158 (0.071)⁎ 0.198 (0.179) −3.530 (1.152)⁎⁎ −0.06
M4:FSFI – – – –
M4:QoL −0.137 (0.075) 0.232 (0.177) −3.437 (1.260)⁎⁎ −0.02
FSFI using Orgasm domain score
M2:FSFI 0.004 (0.007) 0.025 (0.018) −0.003 (0.118) −0.00
M3:QoL −0.149 (0.072)⁎ 0.208 (0.182) −3.584 (1.172)⁎⁎ −0.07
M4:FSFI – – – –
M4:QoL −0.122 (0.076) 0.261 (0.188) −3.454 (1.308)⁎⁎ −0.02
FSFI using Satisfaction domain score
M2:FSFI 0.001 (0.006) −0.009 (0.016) −0.021 (0.103) −0.00
M3:QoL −0.140 (0.071)⁎ 0.271 (0.178) −3.486 (1.145)⁎⁎ −0.04
M4:FSFI – – – –
M4:QoL −0.123 (0.077) 0.293 (0.178) −3.412 (1.263)⁎⁎ −0.01
FSFI using Pain domain score
M2:FSFI 0.001 (0.007) −0.004 (0.018) −0.101 (0.119) −0.00
M3:QoL −0.139 (0.071) 0.250 (0.180) −3.417 (1.160)⁎⁎ −0.05
M4:FSFI – – – –
M4:QoL −0.122 (0.076) 0.273 (0.175) −3.366 (1.263)⁎⁎ −0.01
LSSS: Liverpool Seizure Severity Scale; MARS: Medication Adherence Report Scale.
M1: Model 1, associations between medication adherence and QoL (Fig. 1a); M2: Model 2, ass
associations between sexual functioning and QoL (Fig. 1c); M4: Model 4, associations between
M1, M2, and M3 were analyzed using regression models; M4 using structural equation modeli
a Dependent variable of FSFI included total score and each subdomain score.
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.QoL were correlated (coefﬁcient = 2.538, SE = 1.250, p = 0.04) in
Model 1. Furthermore, objective medication adherence and overall
sexual functioning (coefﬁcient = 2.973, SE = 0.575, p b 0.001)
in Model 2, and overall sexual functioning and QoL were correlated
(coefﬁcient = 0.509, SE = 0.088, p b 0.001) in Model 3.
The objective medication adherence and QoL were not correlated
(coefﬁcient = 0.983, SE = 1.195, p = 0.41) when overall sexual func-
tioning was simultaneously included in Model 4, but overall sexual
functioning was correlated with objective medication adherence
(coefﬁcient = 1.000, SE = 0.047, p b 0.001) and QoL (coefﬁcient =
0.494, SE = 0.083, p b 0.001). Also, mediating effects of the overall
sexual functioning were found (coefﬁcient = 1.980, SE = 0.446,
p b 0.001) in Model 4. These results are shown in Table 3.
According to our analyses, income turned out to be a signiﬁcant
contributor to QoL but not to overall sexual functioning. Moreover, sei-
zure severity measured by LSSS was signiﬁcantly associated with QoL
(coefﬁcient=−0.094, SE= 0.036, p= 0.009) but only when objective
medication adherence was measured and without including sexual
functioning in the model (Table 3).cation adherence (i.e., MARS) and QoL in a sample of 567 female patients with epilepsy.
R2
MARS FSFI Mediating effects of FSFI
7 (0.039) 0.646 (0.142)⁎⁎⁎ – – 0.089
0 (0.015) 0.952 (0.055)⁎⁎⁎ – – 0.439
1 (0.037) – 0.509 (0.088)⁎⁎⁎ – 0.110
1.000 (0.047)⁎⁎⁎ – – 0.434
3 (0.042) 0.250 (0.197) 0.415 (0.115)⁎⁎⁎ 0.415 (0.117)⁎⁎⁎ 0.111
4 (0.003) 0.090 (0.011)⁎⁎⁎ – – 0.162
7 (0.036)⁎ – 1.487 (0.541)⁎⁎ – 0.070
0.096 (0.010)⁎⁎⁎ – – 0.158
5 (0.041) 0.573 (0.164)⁎⁎⁎ 0.755 (0.592) 0.073 (0.057) 0.092
2 (0.003) 0.212 (0.011)⁎⁎⁎ – – 0.487
2 (0.038) – 1.559 (0.433)⁎⁎⁎ – 0.078
0.217 (0.010)⁎⁎⁎ – – 0.481
4 (0.042) 0.537 (0.198)⁎⁎ 0.518 (0.614) 0.112 (0.133) 0.090
2 (0.004) 0.172 (0.015)⁎⁎⁎ – – 0.229
6 (0.036) – 1.884 (0.351)⁎⁎⁎ – 0.103
0.174 (0.014)⁎⁎⁎ – – 0.226
6 (0.041) 0.391 (0.167)⁎ 1.468 (0.406)⁎⁎⁎ 0.255 (0.073)⁎⁎⁎ 0.112
7 (0.004) 0.167 (0.015)⁎⁎⁎ – – 0.264
6 (0.037)⁎ – 1.172 (0.377)⁎⁎ – 0.072
0.178 (0.013)⁎⁎⁎ – – 0.258
2 (0.041) 0.561 (0.174)⁎⁎ 0.524 (0.455) 0.093 (0.083) 0.091
7 (0.004)⁎ 0.133 (0.013)⁎⁎⁎ – – 0.238
8 (0.036) – 2.552 (0.427)⁎⁎⁎ – 0.113
0.145 (0.012)⁎⁎⁎ – – 0.231
1 (0.041) 0.371 (0.164)⁎ 2.093 (0.514)⁎⁎⁎ 0.304 (0.082)⁎⁎⁎ 0.122
7 (0.004) 0.180 (0.015)⁎⁎⁎ – – 0.287
6 (0.037) – 1.795 (0.365)⁎⁎⁎ – 0.095
0.191 (0.013)⁎⁎⁎ – – 0.283
8 (0.042) 0.410 (0.179)⁎ 1.304 (0.445)⁎⁎ 0.249 (0.087)⁎⁎ 0.104
ociations between medication adherence and sexual functioning (Fig. 1b); M3: Model 3,
medication adherence, sexual functioning, and QoL (Fig. 1d).
ng.
Table 3
Mediating effects of sexual functioning in the relationship between objectively assessed medication adherence (i.e., blood serum levels) and QoL in a sample of 567 WWE.
Dependent variablea Independent variable: coefﬁcient (SE) R2
Age Education Income LSSS Serum level FSFI Mediating effects of FSFI
M1:QoL −0.156 (0.072)⁎ 0.215 (0.183) −3.454 (1.175)⁎⁎ −0.094 (0.036)⁎⁎ 2.538 (1.250)⁎ – – 0.063
FSFI using Total score
M2:FSFI −0.042 (0.033) −0.010 (0.084) −0.188 (0.540) −0.134 (0.017)⁎⁎⁎ 2.973 (0.575)⁎⁎⁎ – – 0.175
M4:FSFI – – – – 1.000 (0.047)⁎⁎⁎ – – 0.075
M4:QoL −0.132 (0.078) 0.235 (0.171) −3.433 (1.341)⁎ −0.027 (0.038) 0.983 (1.195) 0.494 (0.083)⁎⁎⁎ 1.980 (0.446)⁎⁎⁎ 0.103
FSFI using Desire domain score
M2:FSFI −0.005 (0.006) 0.002 (0.014) 0.031 (0.092) −0.015 (0.003)⁎⁎⁎ 0.048 (0.098) – – 0.055
M4:FSFI – – – – 0.161 (0.097) – – 0.005
M4:QoL −0.148 (0.078) 0.220 (0.181) −3.570 (1.314)⁎⁎ −0.072 (0.037) 2.394 (1.217)⁎ 1.466 (0.540)⁎⁎ 0.236 (0.173) 0.071
FSFI using Arousal domain score
M2:FSFI −0.017 (0.007)⁎ 0.001 (0.017) −0.037 (0.112) −0.026 (0.003)⁎⁎⁎ 0.563 (0.119)⁎⁎⁎ – – 0.167
M4:FSFI – – – – 0.771 (0.120)⁎⁎⁎ – – 0.066
M4:QoL −0.127 (0.082) 0.227 (0.181) −3.475 (1.275)⁎⁎ −0.055 (0.040) 1.648 (1.223) 1.447 (0.451)⁎⁎ 1.116 (0.390)⁎⁎ 0.071
FSFI using Lubrication domain score
M2:FSFI 0.000 (0.008) 0.010 (0.021) −0.016 (0.136) −0.020 (0.004)⁎⁎⁎ 0.674 (0.145)⁎⁎⁎ – – 0.093
M4:FSFI – – – – 0.828 (0.146)⁎⁎⁎ – – 0.056
M4:QoL −0.157 (0.079)⁎ 0.201 (0.171) −3.452 (1.287)⁎⁎ −0.059 (0.036) 1.298 (1.207) 1.813 (0.372)⁎⁎⁎ 1.500 (0.433)⁎⁎ 0.099
FSFI using Orgasm domain score
M2:FSFI −0.005 (0.008) 0.012 (0.020) −0.006 (0.128) −0.024 (0.004)⁎⁎⁎ 0.679 (0.136)⁎⁎⁎ – – 0.129
M4:FSFI – – – – 0.869 (0.139)⁎⁎⁎ – – 0.066
M4:QoL −0.149 (0.082) 0.213 (0.172) −3.477 (1.289)⁎⁎ −0.068 (0.039) 1.787 (1.246) 1.061 (0.396)⁎⁎ 0.921 (0.379)⁎ 0.070
FSFI using Satisfaction domain score
M2:FSFI −0.005 (0.007) −0.019 (0.017) −0.032 (0.112) −0.021 (0.003)⁎⁎⁎ 0.478 (0.119)⁎⁎⁎ – – 0.114
M4:FSFI – – – – 0.647 (0.120)⁎⁎⁎ – – 0.049
M4:QoL −0.139 (0.080) 0.272 (0.180) −3.407 (1.222)⁎⁎ −0.041 (0.040) 1.337 (1.228) 2.474 (0.473)⁎⁎⁎ 1.600 (0.457)⁎⁎⁎ 0.109
FSFI using Pain domain score
M2:FSFI −0.008 (0.008) −0.017 (0.020) −0.118 (0.132) −0.026 (0.004)⁎⁎⁎ 0.548 (0.141)⁎⁎⁎ – – 0.117
M4:FSFI – – – – 0.757 (0.146)⁎⁎⁎ – – 0.048
M4:QoL −0.139 (0.078) 0.251 (0.176) −3.325 (1.209)⁎⁎ −0.048 (0.040) 1.545 (1.261) 1.722 (0.390)⁎⁎⁎ 1.304 (0.410)⁎⁎ 0.090
LSSS: Liverpool Seizure Severity Scale; MARS: Medication Adherence Report Scale.
M1: Model 1, associations between medication adherence and QoL (Fig. 1a); M2: Model 2, associations between medication adherence and sexual functioning (Fig. 1b); M4: Model 4,
associations between medication adherence, sexual functioning, and QoL (Fig. 1d).
M1 and M2 were analyzed using regression models; M4 using structural equation modeling. We did not report the results of M3 because the results were the same as those on Table 2.
a Dependent variable of FSFI included total score and each subdomain score.
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.
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To the best of our knowledge, this is the ﬁrst study to provide evi-
dence for a mediating effect of certain aspects of sexual functioning in
the relationship between medication adherence and QoL in WWE.
According to our results, sexual functioning improves in women adher-
ing to AED medication which can consequently lead to an increase of
their QoL. However, the strength of the mediating effects of sexual func-
tioning, and of the speciﬁc domains involved, showed different results
depending on whether medication adherence was measured in a sub-
jective or objective way.
Our results ﬁrst showed that both objectively and subjectively mea-
sured medication adherence were signiﬁcantly associated with QoL
in WWE (Model 1), which is in accordance with the results from previ-
ous studies [14,18–20]. We also found that sexual functioning was cor-
related with medication adherence (Model 2). Decreased anxiety
resulted from improvement of the disease symptoms in patients with
good medication adherence [11], which may explain the relationship
between sexual functioning andmedication adherence. Further, consis-
tent with previous study ﬁndings, sexual functioning was signiﬁcantly
correlatedwith QoL in our study (Model 3) [21].When relying on a sub-
jective measure of medication adherence (i.e., MARS), overall sexual
functioning, as well as lubrication, sexual satisfaction, and sexual pain
turned out to be signiﬁcant mediators in the relationship between
medication adherence and QoL (Model 4 in Table 2). In contrast, allFSFI subdomains, except for Desire domain, including the overall FSFI
score, were signiﬁcant mediators in the relationship between AED
serum level (i.e., objective medication adherence) and QoL (Model 4
in Table 3). Based on past reports and our own study ﬁndings, it
seems that higher levels of medication adherence can help improve sei-
zures and related symptoms in WWE [10] which in turn can mean that
they may enjoy their sexual life more without having to worry about
whether their epileptic symptoms will interfere with their sexual
activities and functioning. Speciﬁcally, they can fully enjoy their sexual
life without anxiety. Because of increased enjoyment, QoL may subse-
quently improve.
In terms of the differing results when considering subjective vs. ob-
jective measures of medication adherence, there are various reasons
that could explain this discrepancy. First, some researchers have argued
that AED adherencemay be inﬂuenced by social desirability or memory
bias when relying on subjective measures [14]. Although some argue
that objective measures tend to be more accurate than subjective mea-
sures [33], several studies have reported high correlations between self-
reportedMARS andmeasured AED serum levels [14,30,34]. Second, the
common method bias [35] between the MARS and the FSFI scores may
eliminate or at least signiﬁcantly reduce the effect of sexual functioning
on QoL. That is because both MARS and the FSFI are self-report instru-
ments and participants may choose similar scores in both question-
naires. For example, optimistic people have an overall tendency to
indicate higher scores and may, therefore, have attained higher scores
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tween MARS and the FSFI so that the associations between the FSFI
score and QoL may have been partially transferred to those between
MARS score andQoL. Because of these reasons and thementioned great-
er accuracy of objective measures of medication adherence, we believe
our results of objective measures are more accurate than the results
using the subjective measure, therefore generally indicating a signiﬁ-
cant mediating role of all domains of sexual functioning (apart from
libido) in the relationship between medication adherence and QoL.
Common method bias could also be found in the results involving
symptom severity.When using subjectively reportedmedication adher-
ence, symptom severity was not associated with QoL in our sample,
whereas a signiﬁcant relationship could be observed when relying on
objective blood serum levels. Again, because both MARS and the LSSS
are self-report instruments, commonmethod bias may have been pres-
ent [35].
We were further able to determine signiﬁcant associations between
medication adherence and QoL, which is in line with previous studies
showing that better medication adherence can lead to improved QoL
[18–20]. People with epilepsy report impaired QoL [15,16] due to the
detrimental impact that seizures can have (e.g., physical injuries) and
the high rate of psychiatric and medical comorbidities [36–39].
As is common in longitudinal studies of this and similar nature, there
are some limitations to this study that need to be considered when
interpreting the results. First, althoughwemeasuredmedication adher-
ence six months earlier than the sexual functioning and QoL measure-
ments, sexual functioning and QoL were simultaneously collected.
Therefore, we cannot ensure the temporal relationship between sexual
functioning and QoL, and we did not have strong evidence to support
the mediating role of sexual functioning. Second, because we only
recruited female patients, our results cannot be generalized tomale pa-
tients with epilepsy. Third, sexuality may differ in different cultures and
ethnicities, and our results found in a sample of solely Iranian women
may not generalize to other countries. Fourth, because MARS, FSFI,
and QoL were self-rated, social desirability may incent the participants
to give incorrect information. Lastly, we did not consider different med-
ication effects on our participants. Differentmedicationmay impair sex-
ual functioning views, and subsequently inﬂuence our ﬁndings.
5. Conclusion
Our results point towards a mediating role of sexual functioning in
the relationship between medication adherence and QoL in WWE. In
line with previous studies, we further found a signiﬁcant link between
medication adherence and QoL, as well as between sexual functioning
and medication adherence. Overall, the results underline the impor-
tance of medication adherence not only in terms of symptom reduction
but also further demonstrate how the beneﬁcial effects act more com-
prehensively on QoL. Health care providers should be aware of these
additional beneﬁts of medication adherence and use these insights to
encourage female patients to take their medication, which can
eventually increase their sexual satisfaction and overall QoL.
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